Holen Sie sich die Stockscreener-App
2.13
2.42%
0.06
Schlusskurs vom Vortag:
$2.07
Offen:
$2.08
24-Stunden-Volumen:
270.92K
Relative Volume:
0.10
Marktkapitalisierung:
$722.99M
Einnahmen:
$775.09M
Nettoeinkommen (Verlust:
$-58.68M
KGV:
-16.06
EPS:
-0.1326
Netto-Cashflow:
$64.06M
1W Leistung:
-13.47%
1M Leistung:
-4.07%
6M Leistung:
-50.47%
1J Leistung:
-54.60%
1-Tages-Spanne:
$2.08
$2.13
1-Wochen-Bereich:
$1.77
$2.22
52-Wochen-Spanne:
$1.77
$5.8099
Goodrx Holdings Inc Stock (GDRX) Company Profile
Firmenname
Goodrx Holdings Inc
Sektor
Branche
Telefon
(855) 268-2822
Adresse
2701 OLYMPIC BOULEVARD, SANTA MONICA
Compare GDRX vs VEEV, TEM, BTSG, HQY, WAY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
2.13 | 702.63M | 775.09M | -58.68M | 64.06M | -0.1326 |
|
VEEV
Veeva Systems Inc
|
185.78 | 30.56B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
52.06 | 9.19B | 1.27B | -245.03M | -245.36M | -1.4071 |
|
BTSG
Brightspring Health Services Inc
|
41.93 | 7.33B | 11.99B | 24.18M | 234.31M | 0.2956 |
|
HQY
Healthequity Inc
|
81.79 | 6.87B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
26.60 | 5.09B | 906.14M | -52.62M | 89.62M | -0.3621 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-22 | Herabstufung | Jefferies | Buy → Hold |
| 2025-12-09 | Eingeleitet | Barclays | Underweight |
| 2025-08-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-08-09 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-08-10 | Hochstufung | DA Davidson | Neutral → Buy |
| 2023-07-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | Eingeleitet | Citigroup | Buy |
| 2022-11-04 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-08-12 | Eingeleitet | DA Davidson | Neutral |
| 2022-06-10 | Herabstufung | Goldman | Buy → Neutral |
| 2022-06-06 | Fortgesetzt | BofA Securities | Buy |
| 2022-06-01 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-05-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-04-07 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-03-15 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | Bestätigt | Barclays | Overweight |
| 2022-03-01 | Bestätigt | BofA Securities | Neutral |
| 2022-03-01 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-01 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | Bestätigt | Evercore ISI | Outperform |
| 2022-03-01 | Bestätigt | Goldman | Buy |
| 2022-03-01 | Bestätigt | JP Morgan | Underweight |
| 2022-03-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-03-01 | Bestätigt | SVB Leerink | Outperform |
| 2022-01-07 | Eingeleitet | Goldman | Buy |
| 2021-12-21 | Eingeleitet | Stephens | Overweight |
| 2021-12-02 | Eingeleitet | Jefferies | Buy |
| 2021-08-31 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-08-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-04-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2021-01-25 | Eingeleitet | Guggenheim | Buy |
| 2020-11-19 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | Eingeleitet | Barclays | Equal Weight |
| 2020-10-19 | Eingeleitet | BofA Securities | Neutral |
| 2020-10-19 | Eingeleitet | Citigroup | Buy |
| 2020-10-19 | Eingeleitet | Cowen | Outperform |
| 2020-10-19 | Eingeleitet | Credit Suisse | Outperform |
| 2020-10-19 | Eingeleitet | Deutsche Bank | Hold |
| 2020-10-19 | Eingeleitet | Goldman | Neutral |
| 2020-10-19 | Eingeleitet | JP Morgan | Neutral |
| 2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-10-19 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2020-10-19 | Eingeleitet | UBS | Buy |
Alle ansehen
Goodrx Holdings Inc Aktie (GDRX) Neueste Nachrichten
GDRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
GoodRx (NASDAQ:GDRX) Trading Up 9.4%Should You Buy? - MarketBeat
The Goldman Sachs Group Lowers GoodRx (NASDAQ:GDRX) Price Target to $2.50 - MarketBeat
Goldman Sachs Lowers GoodRx Holdings (GDRX) Price Target to $2.5 - GuruFocus
GoodRx Earnings Call Marks Transitional Reset Year - TipRanks
GDRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX) and Vericel (VCEL) - The Globe and Mail
GoodRx Announces Resignation of Board Member Dipanjan Deb - TipRanks
Why GoodRx (GDRX) Is Down 19.4% After Unveiling Employer Direct And 2026 Revenue Guidance - Yahoo Finance
GoodRx Holdings, Inc.Class A Common Stock (NQ: GDRX - The Chronicle-Journal
GoodRx Holdings (GDRX) Analyst Rating and Price Target Update | - GuruFocus
GoodRx (NASDAQ:GDRX) Given New $3.00 Price Target at Mizuho - MarketBeat
Hims & Hers Expands Digital Health and Global Platform Strategy - TradingView
GoodRx 2026 Guidance Signals Material Reset, Morgan Stanley Says - marketscreener.com
UBS Lowers Price Target on GoodRx Holdings to $2 From $4, Maintains Neutral Rating - marketscreener.com
JPMorgan Chase & Co. Reaffirms Neutral Rating for GoodRx (NASDAQ:GDRX) - MarketBeat
A Glimpse Into The Expert Outlook On GoodRx Holdings Through 4 Analysts - Benzinga
GoodRx Holdings (GDRX) Downgraded by JP Morgan to Neutral | GDRX Stock News - GuruFocus
JPMorgan Downgrades GoodRx to Neutral From Overweight - marketscreener.com
Raymond James cuts GoodRx stock price target on pharma headwinds By Investing.com - Investing.com South Africa
GoodRx Q4 2025 Earnings: Revenue Down, Future Guidance Below EstimatesNews and Statistics - IndexBox
GoodRx Holdings, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Leerink Maintains Outperform on GoodRx (GDRX) Feb 26, 2026 PT $3 - Meyka
JPMorgan Downgrades GoodRx Holdings Inc. (GDRX) to Neutral - StreetInsider
GoodRx Holdings Inc. (GDRX) PT Lowered to $1.90 at BofA Securities - StreetInsider
GoodRx Holdings Inc (GDRX) Q4 2025 Earnings Call Highlights: Pha - GuruFocus
GoodRx expects Pharma Direct revenue growth of at least 30% in 2026 amid shift to pharma manufacturer solutions - MSN
GoodRx (GDRX) Q4 2025 Earnings Call Transcript - AOL.com
Leerink cuts GoodRx stock price target to $3 on weak guidance - Investing.com Australia
GoodRx Holdings Inc. (GDRX) PT Lowered to $3 at Leerink Partners - StreetInsider
GoodRx (NASDAQ:GDRX) Sets New 52-Week LowHere's What Happened - MarketBeat
GDRX: Pharma Direct revenue surged 41% in 2025, driving growth amid evolving healthcare trends - TradingView
Earnings call transcript: GoodRx Q4 2025 revenue meets expectations amid strategic shifts - Investing.com
GDRX: Pharma Direct and subscriptions drive growth amid near-term revenue pressure and strategic shifts - TradingView
Here's What Key Metrics Tell Us About GoodRx (GDRX) Q4 Earnings - Yahoo Finance
Q4 2025 GoodRx Holdings Inc Earnings Call Transcript - GuruFocus
GoodRx Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
GoodRx Holdings Inc. (GDRX) Stock Falls on Q4 2025 Earnings - Quiver Quantitative
GoodRx Reports Fourth Quarter and Full Year 2025 Results - PharmiWeb.com
GoodRx (GDRX) Sees High Call Activity Ahead of Earnings - GuruFocus
GoodRx Holdings options imply 10.2% move in share price post-earnings - TipRanks
GoodRx’s (NASDAQ:GDRX) Q4 CY2025 Sales Top Estimates But Stock Drops 11.8% - Yahoo Finance
GoodRx (NASDAQ:GDRX) Announces Quarterly Earnings Results, Meets Estimates - MarketBeat
GoodRx Holdings, Inc. (GDRX) Reports In-Line Q4 EPS ; Offers Guidance - StreetInsider
GDRX: Pharma Direct revenue surged 41% in 2025, offsetting declines in other segments - TradingView
GoodRx Holdings, Inc. Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
GoodRx Holdings, Inc. (GDRX) Investor Outlook: Exploring A Potential 100% Upside - DirectorsTalk Interviews
GoodRx Holdings, Inc. Expands into Employer Market with Launch of "Goodrx Employer Direct" - marketscreener.com
Employers get new way to cut Wegovy and GLP-1 costs with GoodRx - Stock Titan
GoodRx (GDRX) Reports Earnings Tomorrow: What To Expect - Finviz
GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Finanzdaten der Goodrx Holdings Inc-Aktie (GDRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):